NASDAQ:MLTX MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis $15.19 +0.13 (+0.86%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MLTX alerts:Sign Up Key Stats Today's Range$14.98▼$15.4550-Day Range$14.99▼$20.4152-Week Range$5.95▼$62.75Volume841,886 shsAverage Volume1.38 million shsMarket Capitalization$1.29 billionP/E RatioN/ADividend YieldN/APrice Target$24.57Consensus RatingHold Company Overview MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. Read More MoonLake Immunotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreMLTX MarketRank™: MoonLake Immunotherapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 698th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on no strong buy ratings, 10 buy ratings, 4 hold ratings, and 3 sell ratings.Upside PotentialMoonLake Immunotherapeutics has a consensus price target of $24.57, representing about 61.8% upside from its current price of $15.19.Amount of Analyst CoverageMoonLake Immunotherapeutics has only been the subject of 4 research reports in the past 90 days.Read more about MoonLake Immunotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($3.34) to ($3.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MoonLake Immunotherapeutics is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MoonLake Immunotherapeutics is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoonLake Immunotherapeutics has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MoonLake Immunotherapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.94% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 4.22.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently increased by 19.17%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMoonLake Immunotherapeutics does not currently pay a dividend.Dividend GrowthMoonLake Immunotherapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest7 people have searched for MLTX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MoonLake Immunotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,820,071.00 in company stock.Percentage Held by Insiders10.40% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MoonLake Immunotherapeutics' insider trading history. Receive MLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLTX Stock News HeadlinesMoonLake Immunotherapeutics (MLTX)August 23, 2026 | finance.yahoo.comMoonLake’s psoriatic arthritis drug shows promise in phase 3 trial – retail shrugs off premarket slide, says ‘pipeline is intact’August 11, 2026 | msn.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 3 at 1:00 AM | The Oxford Club (Ad)MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical GoalsAugust 10, 2026 | finance.yahoo.comMoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...August 10, 2026 | markets.businessinsider.comMoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage StudyAugust 10, 2026 | benzinga.comMoonLake's psoriatic arthritis drug meets key goals in late-stage trialAugust 10, 2026 | reuters.comMoonLake announces positive Phase 3 psoriatic arthritis resultsAugust 10, 2026 | tipranks.comSee More Headlines MLTX Stock Analysis - Frequently Asked Questions How have MLTX shares performed this year? MoonLake Immunotherapeutics' stock was trading at $13.18 on January 1st, 2026. Since then, MLTX shares have increased by 15.3% and is now trading at $15.19. How were MoonLake Immunotherapeutics' earnings last quarter? MoonLake Immunotherapeutics (NASDAQ:MLTX) announced its quarterly earnings data on Monday, August, 10th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.07. When did MoonLake Immunotherapeutics IPO? MoonLake Immunotherapeutics (MLTX) raised $100 million in an initial public offering on Tuesday, October 20th 2020. The company issued 10,000,000 shares at $10.00 per share. Who are MoonLake Immunotherapeutics' major shareholders? MoonLake Immunotherapeutics' top institutional investors include California State Teachers Retirement System (0.87%), Headlands Technologies LLC (0.07%) and FNY Investment Advisers LLC. Insiders that own company stock include Da Silva Jorge Santos, Kristian Reich, Bvf Partners L P/Il, Matthias Bodenstedt and Simon Sturge. View institutional ownership trends. How do I buy shares of MoonLake Immunotherapeutics? Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MoonLake Immunotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Disc Medicine (IRON), e.l.f. Beauty (ELF), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Arista Networks (ANET). Company Calendar Last Earnings8/10/2026Today9/03/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 10 days, MLTX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MLTX CIK1821586 Webwww.moonlaketx.com Phone41-41-510-8022FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Price Target for MoonLake Immunotherapeutics$24.57 High Price Target$50.00 Low Price Target$8.00 Potential Upside/Downside+61.8%Consensus RatingHold Rating Score (0-4)2.41 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($3.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$227.32 million Net MarginsN/A Pretax MarginN/A Return on Equity-82.53% Return on Assets-58.17% Debt Debt-to-Equity Ratio0.23 Current Ratio12.56 Quick Ratio12.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.03 per share Price / Book3.02Miscellaneous Outstanding Shares85,107,000Free Float76,256,000Market Cap$1.29 billion OptionableOptionable Beta1.04 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:MLTX) was last updated on 9/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
